stella
← For Researchers/Sickle Cell Disease/Research Sites

Sickle Cell Disease Research Sites

Sites currently running trials · ranked by activity

EndometriosisLong COVIDALSPTSDSickle Cell DiseaseLupusProstate CancerMenopause

449 sites · 529 trials · June 2026

Recruiting
Opening soon
Active · not recruiting
1

National Institutes of Health Clinical Center

Bethesda · Maryland · United States

7 trials
Partial stem cell transplant from matched donors for patients with severe sickle cell disease or beta-thalassemia requiring blood transfusions.
National Heart, Lung, and Blood Institute (NHLBI)Ph 1 / Ph 2RecruitingNCT07599176 ↗
Research examines how genetic variants in the PKLR gene affect sickle cell disease severity and red blood cell function.
National Heart, Lung, and Blood Institute (NHLBI)RecruitingNCT03685721 ↗
Skin gel formulation VAS-101 containing curcumin to improve red blood cell health in stable sickle cell disease patients.
National Heart, Lung, and Blood Institute (NHLBI)Ph 1NCT07566494 ↗
2

Boston Medical Center

Boston · Massachusetts · United States

5 trials
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
3

St. Jude Children's Research Hospital

Memphis · Tennessee · United States

4 trials
Adherence monitoring strategies for hydroxyurea therapy in youth with sickle cell disease to improve treatment compliance.
St. Jude Children's Research HospitalNCT03708731 ↗
Biological samples and health data collected from blood disease patients for genetic research studies.
St. Jude Children's Research HospitalRecruitingNCT02720679 ↗
Research examines reproductive hormone levels in adolescent girls with sickle cell disease and effects of treatment on fertility.
St. Jude Children's Research HospitalRecruitingNCT07392216 ↗
4

Boston Children's Hospital

Boston · Massachusetts · United States

2 trials
Gene therapy using lentivirus vector to induce fetal hemoglobin production in patients with sickle cell disease.
David WilliamsNCT07640815 ↗
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
5

UCSF Benioff Children's Hospital Oakland

Oakland · California · United States

2 trials
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
6

Emory University

Atlanta · Georgia · United States

2 trials
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
7

East Carolina University

Greenville · North Carolina · United States

2 trials
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
8

Phoenix Children's Hsptl

Phoenix · Arizona · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
9

Children's Hospital Los Angeles - Endocrinology

Los Angeles · California · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
10

University Of California Irvine

Orange · California · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
11

Children's Healthcare Atlanta

Atlanta · Georgia · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
12

Univer Of Illinois at Chicago

Chicago · Illinois · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
13

Children's Hosp-New Orleans

New Orleans · Louisiana · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3CompletedNCT06609226 ↗
14

Washington University-St.Louis

St Louis · Missouri · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
15

NYC Health+Hospitals

Brooklyn · New York · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
16

Jacobi Medical Center

The Bronx · New York · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
17

Duke University Medical Center

Durham · North Carolina · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
18

East Carolina Univ-Greenville

Greenville · North Carolina · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
19

Atrium Health-Wake Forest Bapt

Winston-Salem · North Carolina · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
20

UT Health University of Texas

Houston · Texas · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
21

Virginia Comm Univ Medical Ctr

Richmond · Virginia · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
22

Mary Bridge Children's Health

Tacoma · Washington · United States

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
23

St Pauls Hospital

Vancouver · British Columbia · Canada

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
24

Ap-Hp-Hopital Henri Mondor

Créteil · France

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
25

Hospices Civils de Lyon-Hopital Edouard Herriot

Lyon · France

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
26

Ap-Hp-Hopital Robert Debre

Paris · France

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
27

Kintampo Health Research Centre (KHRC)

Kintampo · Bono East · Ghana

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
28

Hippokration Hospital

Athens · Greece

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
29

All India Institute of Medical Sciences (AIIMS), Raipur

Raipur · Chhattisgarh · India

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
30

Azienda Ospedaliera Universitaria San Luigi Gonzaga - S.C.D.O. Microcitemie e malattie rare ematologiche

Orbassano · Torino · Italy

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
31

Azienda Ospedale Universita Padova

Padova · Italy

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
32

Gertrude's Children's Hospital

Nairobi · Nairobi County · Kenya

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
33

KEMRI CRDR Siaya Clinical Research Annex, Country Referral Hospital

Siaya · Siaya County · Kenya

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
34

Ahero Clinical Trials Unit

Kisumu · Kenya

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
35

American University of Beirut Medical Centre

Hamra · Lebanon

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
36

Hospital Nini

Tripoli · Lebanon

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
37

University of Nigeria Teaching Hospital (UNTH)

Ituku-Ozalla · Enugu State · Nigeria

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
38

University College Hospital Paediatric Haematology and Oncology Unit, Ibadan

Ibadan · Oyo State · Nigeria

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
39

Lagos University Teaching Hospital, Lagos

Lagos · Nigeria

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
40

Sultan Qaboos University Hospital

Muscat · Sultanet of Oman/Muscat/Al Khoud · Oman

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
41

King Khalid University Hospital

Riyadh · Saudi Arabia

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
42

Hospital Vall d'Hebron

Barcelona · Spain

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
43

Hospital Universitario La Paz

Madrid · Spain

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
44

Başkent Üniversitesi Adana-Hematoloji

Adana · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
45

Hacettepe University Hematology

Ankara · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
46

Hacettepe Üniversitesi Hastanesi- Hematoloji

Ankara · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
47

Mersin University Medical Faculty Pediatric Hematology

Mersin · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
48

Mersin Üniversitesi Tip Fakültesi Hastanesi- Çiftlikköy Yerleşkesi- Hematoloji

Mersin · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
49

VM Medical Park Mersin Hastanesi- Hematoloji

Mersin · Turkey (Türkiye)

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
50

Guy's Hospital - Haematology

London · United Kingdom

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
51

King's College Hospital - Paediatric Research

London · United Kingdom

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
52

Kings College Hospital - Haematology

London · United Kingdom

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
53

Imperial College London

London · United Kingdom

2 trials
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
54

University of Alabama at Birmingham

Birmingham · Alabama · United States

2 trials
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
55

Novartis Investigative Site

Brussels · Belgium

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
56

Novartis Investigative Site

Salvador · Estado de Bahia · Brazil

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
57

Novartis Investigative Site

Ribeirão Preto · São Paulo · Brazil

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
58

Novartis Investigative Site

São Paulo · São Paulo · Brazil

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
59

Novartis Investigative Site

Barranquilla · Atlántico · Colombia

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
60

Novartis Investigative Site

Valledupar · Cesar Department · Colombia

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
61

Novartis Investigative Site

Montería · Colombia

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
62

Novartis Investigative Site

Créteil · France

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
63

Novartis Investigative Site

Paris · France

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
64

Novartis Investigative Site

Beirut · Lebanon

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
65

Novartis Investigative Site

Tripoli · Lebanon

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
66

Novartis Investigative Site

Khoudh · Oman

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
67

Novartis Investigative Site

Barcelona · Spain

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
68

Novartis Investigative Site

Madrid · Spain

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
69

Novartis Investigative Site

Adana · Saricam · Turkey (Türkiye)

2 trials
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
70

Cincinnati Children's Hospital Medical Center

Cincinnati · Ohio · United States

2 trials
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
Losartan medication to reduce heart scarring in sickle cell disease patients aged 6+.
Children's Hospital Medical Center, CincinnatiPh 2NCT05012631 ↗
71

Massachusetts General Hospital

Boston · Massachusetts · United States

1 trial
Virtual reality supportive care intervention called Amani to improve coping and peer support for adults with sickle cell disease.
Massachusetts General HospitalPh 1 (early)NCT07648043 ↗
72

Hôpital Victor Dupouy (CH Argenteuil)

Argenteuil · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
73

CHI Robert Ballanger

Aulnay-sous-Bois · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
74

Hôpital Jean Verdier

Bondy · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
75

Hôpital Pellegrin - Hôpital des Enfants

Bordeaux · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
76

Hôpital Ambroise Paré

Boulogne-Billancourt · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
77

Hôpital Saint Camille

Bry-sur-Marne · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
78

Hôpital NOVO

Cergy-Pontoise · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
79

Hôpital Antoine Béclère

Clamart · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
80

CH Sud Francilien

Corbeil-Essonnes · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
81

CHI Créteil

Créteil · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
82

CH du Sud Seine et Marne

Fontainebleau · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
83

CH Gonesse

Gonesse · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
84

GHEF, Site de Marne-la-Vallée

Jossigny · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
85

Hôpital Bicêtre

Le Kremlin-Bicêtre · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
86

GHT Yvelines Nord

Mantes-la-Jolie · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
87

Hôpital Nord, AP-HM

Marseille · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
88

GHEF, Site de Meaux

Meaux · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
89

GH Sud Ile-de-france

Melun · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
90

GHI Le Raincy-Montfermeil

Montfermeil · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
91

CHU Nantes

Nantes · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
92

CH Rives de Seine, Site de Neuilly-sur-Seine

Neuilly-sur-Seine · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
93

CHU Lenval

Nice · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
94

Hôpital Paris-Saclay

Orsay · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
95

Hôpital Necker

Paris · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
96

Hôpital Robert Debré

Paris · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
97

Hôpital Trousseau

Paris · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
98

CHI Poissy

Poissy · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
99

CH Rambouillet

Rambouillet · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
100

CH Saint Denis, Hôpital Delafontaine

Saint-Denis · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
101

Hôpital André Mignot

Versailles · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
102

Hôpital Intercommunal Villeneuve-St-Georges

Villeneuve-Saint-Georges · France

1 trial
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.
Assistance Publique - Hôpitaux de ParisNCT07639008 ↗
103

St Jude Children's Research Hospital

Memphis · Tennessee · United States

1 trial
Reduced toxicity stem cell transplant from half-matched donors with post-transplant cyclophosphamide for children with sickle cell disease.
St. Jude Children's Research HospitalPh 2NCT07616154 ↗
104

Nalufenya Childrens

Jinja · Uganda

1 trial
Mobile health screening system in Uganda to improve newborn sickle cell disease detection and coordinated care access.
Makerere UniversityRecruitingNCT07610239 ↗
105

University of Alabama

Tuscaloosa · Alabama · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
106

Howard University Center for Sickle Cell Disease

Washington D.C. · District of Columbia · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
107

University of Illinois at Chicago

Chicago · Illinois · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
108

University of Maryland

Baltimore · Maryland · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
109

Johns Hopkins University

Baltimore · Maryland · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
110

Washington University-St. Louis

St Louis · Missouri · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
111

Icahn School of Medicine at Mount Sinai

New York · New York · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
112

Montefiore Medical Center

New York · New York · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
113

University of North Carolina at Chapel Hill

Chapel Hill · North Carolina · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
114

Atrium Health

Charlotte · North Carolina · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
115

Duke University

Durham · North Carolina · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
116

University Hospitals Cleveland Medical Center

Cleveland · Ohio · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
117

Ohio State University

Columbus · Ohio · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
118

University of Pittsburgh Medical Center

Pittsburgh · Pennsylvania · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
119

University of Texas Health Science Center at Houston

Houston · Texas · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
120

Virginia Commonwealth University

Richmond · Virginia · United States

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
121

Hemorio

Rio de Janeiro · Brazil

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
122

Kremlin-Bicêtre

Créteil · France

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
123

Henri Mondor Hopital

Paris · France

1 trial
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.
University of PittsburghPh 3NCT04084080 ↗
124

Indiana University

Indianapolis · Indiana · United States

1 trial
Ultrasound imaging feasibility and reliability for diagnosing acute chest syndrome in hospitalized sickle cell patients.
Indiana UniversityRecruitingNCT06880679 ↗
125

University of Chicago

Chicago · Illinois · United States

1 trial
Tocilizumab drug to treat acute chest syndrome complications in sickle cell disease patients.
University of ChicagoPh 2RecruitingNCT05640271 ↗
126

University of Illinois Chicago

Chicago · Illinois · United States

1 trial
Mediterranean diet comparison to usual diet for pain management in sickle cell disease patients.
University of Illinois at ChicagoRecruitingNCT06886477 ↗
127

University of California, Irvine

Irvine · California · United States

1 trial
Exercise intervention study in children, collaboration across three major NIH research centers.
University of California, IrvineRecruitingNCT05359991 ↗
128

Mayo Clinic Division of Nursing

Rochester · Minnesota · United States

1 trial
Songwriting therapy to reduce anxiety in adolescents with sickle cell disease.
Mayo ClinicRecruitingNCT07222475 ↗
129

Children's Hospital of Atlanta: Eagelston

Atlanta · Georgia · United States

1 trial
Nerve stimulation device to reduce pain in children with sickle cell disease.
Emory UniversityRecruitingNCT07090668 ↗
130

Inova Schar Cancer

Fairfax · Virginia · United States

1 trial
Early heart screening and iron treatment to prevent heart complications in sickle cell disease patients.
Inova Health Care ServicesPh 2RecruitingNCT07023666 ↗
131

Inova Health Care Service

Falls Church · Virginia · United States

1 trial
Early heart screening and iron treatment to prevent heart complications in sickle cell disease patients.
Inova Health Care ServicesPh 2RecruitingNCT07023666 ↗
132

City of Hope Medical Center

Duarte · California · United States

1 trial
Plerixafor injections mobilize blood stem cells for transplant in sickle cell disease patients.
City of Hope Medical CenterPh 1NCT03664830 ↗
133

Dermatology unit - Cochin Hospital - APHP

Paris · Île-de-France Region · France

1 trial
Study identifies chemokine receptors on fetal cells in postpartum women with and without wounds.
Assistance Publique - Hôpitaux de ParisRecruitingNCT06031714 ↗
134

Children's Hospital of Pittsburgh of UPMC

Pittsburgh · Pennsylvania · United States

1 trial
Mismatched donor stem cell transplant treats sickle cell disease and transfusion-dependent anemias.
Paul SzabolcsPh 1 / Ph 2RecruitingNCT03653338 ↗
135

University of Florida

Gainesville · Florida · United States

1 trial
Mobile app teaches stress and pain self-management to reduce opioid use in sickle cell patients.
University of FloridaRecruitingNCT04484272 ↗
136

Children's Healthcare fo Atlanta at Hughes Spalding

Atlanta · Georgia · United States

1 trial
Arginine supplementation reduces pain severity and hospital visits in children with sickle cell disease.
Emory UniversityPh 1 / Ph 2RecruitingNCT02447874 ↗
137

Children's Healthcare of Atlanta at Arthur M. Blank Hospital

Atlanta · Georgia · United States

1 trial
Arginine supplementation reduces pain severity and hospital visits in children with sickle cell disease.
Emory UniversityPh 1 / Ph 2RecruitingNCT02447874 ↗
138

Chu de La Guadeloupe

Pointe-à-Pitre · Guadeloupe

1 trial
Study examines why sickle cell patients develop more severe dengue virus infections.
Centre Hospitalier Universitaire de la GuadeloupeRecruitingNCT07000747 ↗
139

Uni of Alabama at Birmingham

Birmingham · Alabama · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
140

Univer South Alabama Ped/Onc

Mobile · Alabama · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
141

Arkansas Children's Hospital

Little Rock · Arkansas · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
142

UCLA Health

Los Angeles · California · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
143

Valley Children's Hospital

Madera · California · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
144

Stanford University_Palo Alto

Palo Alto · California · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
145

Harbor-UCLA Medical Center

Torrance · California · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
146

Clinical and Transl Res Center

Aurora · Colorado · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
147

Nemours/AI duPont Hosp-Chld

Wilmington · Delaware · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
148

Childrens National Medical Ctr

Washington D.C. · District of Columbia · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
149

MedStar Hlth Res Institute

Washington D.C. · District of Columbia · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
150

Memorial Healthcare

Hollywood · Florida · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
151

Childrens Hospital of Chicago

Chicago · Illinois · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
152

Henry Ford Hospital_Detroit

Detroit · Michigan · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
153

University of Minnesota

Minneapolis · Minnesota · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
154

Children's Nebraska

Omaha · Nebraska · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
155

Cure 4 the Kids Foundation

Las Vegas · Nevada · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
156

Newark Beth Israel MC

Newark · New Jersey · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
157

Interfaith Medical Center

Brooklyn · New York · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
158

Northwell Health

Mount Kisco · New York · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
159

Cohen Children's Medical Ctr

Queens · New York · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
160

Montefiore Medical Ctr

The Bronx · New York · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
161

Duke Comprehen Sickle Cell

Durham · North Carolina · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
162

Univ Hosp Cleveland Med Ctr

Cleveland · Ohio · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
163

Ohio State Univ Wexner Med Ctr

Columbus · Ohio · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
164

Univ of OK Health Sciences Ctr

Oklahoma City · Oklahoma · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
165

Children's Hosptl Philadelphia

Philadelphia · Pennsylvania · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
166

St Christopher Hosp for Child

Philadelphia · Pennsylvania · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
167

University of Tennessee Health Science Center

Memphis · Tennessee · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
168

St. Jude Children's Res Hosp

Memphis · Tennessee · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
169

Inova Health System

Fairfax · Virginia · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
170

Children's Hsptl Of The Kings

Norfolk · Virginia · United States

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
171

Royal Prince Alfred Hospital - Department of Haematology

Camperdown · New South Wales · Australia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
172

Prince of Wales Hospital - Department of Haematology

Randwick · New South Wales · Australia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
173

Monash Medical Centre - Haematology Department

Clayton · Victoria · Australia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
174

Fiona Stanley Hospital - Haemophilia and Haemostasis Centre

Murdoch · Western Australia · Australia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
175

CHU Saint-Pierre - UMC Sint-Pieter

Brussels · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
176

CHU - UVC Brugmann

Brussels · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
177

HUB - Hôpital Erasme

Brussels · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
178

UZ Antwerpen - UZA - Haematology

Edegem · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
179

UZ Antwerpen - UZA - Kinderhemato-Oncologie

Edegem · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
180

UZ Leuven - Kindergeneeskunde

Leuven · Belgium

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
181

MultiHemo - Grupo Oncoclínicas

Recife · Pernambuco · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
182

Hemocentro UNICAMP

Distrito de Barão Geraldo - Campinas · São Paulo · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
183

HC da FMUSP Hospital das Clínicas São Paulo

São Paulo · São Paulo · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
184

Fundação Hemocentro de Ribeirão Preto

Ribeirão Preto · São · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
185

Hemorio-Fundarj

Rio de Janeiro · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
186

Hospital Samaritano Higienópolis - Instituto de Conhecimento Ensino e Pesquisa (ICEP)

São Paulo · Brazil

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
187

Foothills Med Ctr-Univ Calgary

Calgary · Alberta · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
188

Stollery Children's Hospital

Edmonton · Alberta · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
189

University of Alberta_Edmonton

Edmonton · Alberta · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
190

BC Children's Hospital

Vancouver · British Columbia · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
191

LHSC - Victoria Hospital

London · Ontario · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
192

Scarborough Health Network Research Institute (SHNRI)

Scarborough Village · Ontario · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
193

UHN-Toronto General Hospital

Toronto · Ontario · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
194

University of Toronto

Toronto · Ontario · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
195

CHUM-Hosp de Univ Montreal

Montreal · Quebec · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
196

Montreal Children's Hospital

Montreal · Quebec · Canada

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
197

Hospital Pablo Tobon Uribe

Medellín · Antioquia · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
198

Clinica de la Costa

Barranquilla · Atlántico · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
199

Sociedad de Oncología y Hematología del Cesar SAS (SOHEC)

Valledupar · Cesar Department · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
200

Clínica IMAT Oncomedica Auna S.A.S.

Montería · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
201

Fundacion Valle del Lili

Cali · Valle del Cauca Department · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
202

Sociedad de Oncología y Hematología del Cesar SAS (SOHEC)

Antioquia · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
203

Centro de investigaciones clínicas, fudación valle del lili

Cali · Colombia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
204

Ap-Hp-Hopital Avicenne

Bobigny · France

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
205

Centre Hospitalier Universitaire de Bordeaux-Hopital Pellegrin

Bordeaux · France

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
206

Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon

Grenoble · France

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
207

AP-HP-HOPITAL NECKER_Service d'hématologie

Paris · France

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
208

Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle

Rouen · France

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
209

Navrongo Health Research Centre

Navrongo · Upper East Region · Ghana

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
210

Agogo Presbyterian Hospital, Ghana

Agogo · Ghana

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
211

"Laiko" General Hospital of Athens

Athens · Greece

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
212

Childrens' Hospital of Athens "Agia Sofia"

Athens · Greece

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
213

University General Hospital Of Ioannina

Ioannina · Greece

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
214

"AHEPA" University General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
215

Gauhati Medical College and Hospital

Guwahati · Assam · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
216

Zydus Medical College & Hospital

Dohad · Gujarat · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
217

Nirmal Hospital Pvt. Ltd.

Surat · Gujarat · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
218

SSG Hospital, Baroda

Vadodara · Gujarat · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
219

HOCC Haemato Oncology Care Centre

Vadodara · Gujarat · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
220

JSS Hospital, Mysore

Mysuru · Karnataka · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
221

Government Medical College, Kozhikode

Kozhikode · Kerala · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
222

Arihant Multispeciality Hospital

Nagpur · Maharashtra · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
223

IMS and SUM Hospital

Bhubaneswar · Odisha · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
224

RNT Medical College

Udaipur · Rajasthan · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
225

NIZAM'S Institute of Medical Sciences

Hyderabad · Telangana · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
226

Post Graduate Institute of Child Health

Noida · Uttar Pradesh · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
227

All India Institute of Medical Sciences_New Dehli

New Delhi · India

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
228

Azienda Ospedaliera Universitaria San Luigi Gonzaga

Orbassano · Torino · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
229

Azienda Ospedaliera Universitaria Integrata Verona Policlinico GB Rossi - Borgo Roma - Centro Ricerche Cliniche Di Verona S.r.l.

Verona · Veneto · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
230

ASST Civili di Brescia

Brescia · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
231

ARNAS Garibaldi Catania - Presidio Ospedaliero Garibaldi-Centro

Catania · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
232

Azienda Ospedaliero Universitaria Di Modena - UOC Pediatria ad indirizzo Oncoematologico

Modena · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
233

Fondazione IRCCS San Gerardo dei Tintori

Monza · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
234

A.O.U. Università Studi della Campania "Luigi Vanvitelli"

Naples · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
235

Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello

Palermo · Italy

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
236

International Cancer Institute (ICI)

Eldoret · Uasin Gishu County · Kenya

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
237

AmsterdamUMC VUMC - Hematologie

Amsterdam · Netherlands

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
238

Erasmus MC

Rotterdam · Netherlands

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
239

HagaZiekenhuis

The Hague · Netherlands

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
240

UMC Utrecht, Van Creveldkliniek

Utrecht · Netherlands

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
241

Centre of Excellence for Sickle Cell Disease Research and Training, University of Abuja (CESRTA)

Abuja · Federal Capital Territory (fct) · Nigeria

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
242

The Royal Hospital

Muscat · Oman

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3CompletedNCT06612268 ↗
243

King Abdulaziz Hospital-Al Ahsa-National Guard

Al Ahsa · Saudi Arabia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
244

Prince Mohammed bin Fahad Hospital for Blood Disorders

Al Qaţīf · Saudi Arabia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
245

National Guard Hospital Dammam

Dhahran · Saudi Arabia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
246

King Faisal Specialist Hospital & Research Centre, Riyadh

Riyadh · Saudi Arabia

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
247

Hospital Gregorio Marañón

Madrid · Spain

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
248

Hospital Universitario Virgen del Rocío

Seville · Spain

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
249

Acıbadem Adana Hastanesi-Hematoloji

Adana · Turkey (Türkiye)

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
250

Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi- Hematoloji

Adana · Turkey (Türkiye)

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
251

Makerere University College of Health Sciences (MakCHS)

Kampala · Central Region · Uganda

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
252

Joint Clinical Research Centre (JCRC)

Kampala · Central Region (Wakiso District) · Uganda

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
253

Jinja Regional Referral Hospital

Jinja · Eastern Region · Uganda

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3Opening soonNCT06612268 ↗
254

Addenbrooke's Hospital - Haemophilia and Thrombophilia

Cambridge · United Kingdom

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
255

Whittington Hospital

London · United Kingdom

1 trial
Etavopivat drug to reduce vaso-occlusive crises and organ damage in adolescents and adults with sickle cell disease.
Novo Nordisk A/SPh 3RecruitingNCT06612268 ↗
256

University of California San Diego - La Jolla

La Jolla · California · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
257

Yale-New Haven Hospital

New Haven · Connecticut · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
258

Local Institution - 0035

Tampa · Florida · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
259

Winship Cancer Institute of Emory University

Atlanta · Georgia · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
260

Local Institution - 0034

Chicago · Illinois · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
261

Local Institution - 0001

Lenexa · Kansas · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2ActiveNCT06481306 ↗
262

Local Institution - 0064

Baltimore · Maryland · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
263

Local Institution - 0024

Boston · Massachusetts · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
264

Local Institution - 0030

St Louis · Missouri · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
265

Local Institution - 0033

Greenville · North Carolina · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
266

Local Institution - 0028

Cleveland · Ohio · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
267

Local Institution - 0029

Philadelphia · Pennsylvania · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
268

Thomas Jefferson University - Medicine/GI and Hepatology

Philadelphia · Pennsylvania · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
269

Local Institution - 0032

Pittsburgh · Pennsylvania · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
270

Local Institution - 0027

Greenville · South Carolina · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
271

Inova Schar Cancer Institute

Fairfax · Virginia · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
272

Virginia Commonwealth University (VCU) Medical Center

Richmond · Virginia · United States

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
273

Local Institution - 0050

Vancouver · British Columbia · Canada

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
274

Local Institution - 0051

Toronto · Ontario · Canada

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
275

Institut de cancérologie Strasbourg Europe (ICANS)

Strasbourg · Alsace · France

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
276

Local Institution - 0061

Créteil · France

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
277

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille · France

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
278

Hôpital Universitaire Necker Enfants Malades

Paris · France

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
279

Local Institution - 0011

Milan · Lombardy · Italy

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
280

Local Institution - 0037

Padua · Italy

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
281

Local Institution - 0009

Verona · Italy

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
282

University Hospitals Sussex NHS Foundation Trust

East Sussex · Brighton And Hove · United Kingdom

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
283

Local Institution - 0044

London · Greater London · United Kingdom

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
284

King's College Hospital

London · London, City of · United Kingdom

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2RecruitingNCT06481306 ↗
285

Local Institution - 0005

Leeds · United Kingdom

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
286

Local Institution - 0047

London · United Kingdom

1 trial
BMS-986470 drug tested for safety and effectiveness in healthy people and sickle cell disease patients.
Bristol-Myers SquibbPh 1 / Ph 2Opening soonNCT06481306 ↗
287

Nemours Children's Hospital, Delaware

Wilmington · Delaware · United States

1 trial
Shared decision-making intervention tested with teenagers and young adults with sickle cell disease and their caregivers.
Nemours Children's ClinicRecruitingNCT05383911 ↗
288

Makerere University

Kampala · Uganda

1 trial
Study tracking sickle cell disease prevalence, survival rates, and health outcomes in Ugandan children.
Children's Hospital Medical Center, CincinnatiRecruitingNCT06301893 ↗
289

Minister of Health

Kampala · Uganda

1 trial
Study tracking sickle cell disease prevalence, survival rates, and health outcomes in Ugandan children.
Children's Hospital Medical Center, CincinnatiRecruitingNCT06301893 ↗
290

National Coordinator EID Program

Kampala · Uganda

1 trial
Study tracking sickle cell disease prevalence, survival rates, and health outcomes in Ugandan children.
Children's Hospital Medical Center, CincinnatiRecruitingNCT06301893 ↗
291

Sickle Cell Clinic Department of Pediatrics & Child Health Mulago Hospital

Kampala · Uganda

1 trial
Study tracking sickle cell disease prevalence, survival rates, and health outcomes in Ugandan children.
Children's Hospital Medical Center, CincinnatiRecruitingNCT06301893 ↗
292

Penn Medicine University City

Philadelphia · Pennsylvania · United States

1 trial
Progestin implant contraceptive tested in women with sickle cell disease for safety and pain crisis reduction.
University of PennsylvaniaPh 4NCT05730205 ↗
293

Columbia University Irving Medical Center

New York · New York · United States

1 trial
Radioactive apamistamab used to prepare severely ill sickle cell patients for bone marrow transplants.
Columbia UniversityPh 1RecruitingNCT07015684 ↗
294

Univ of Alabama Birmingham

Birmingham · Alabama · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
295

UCSF Oakland Benioff ChildHosp

Oakland · California · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
296

Children's Hosp Of Orange

Orange · California · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3CompletedNCT06609226 ↗
297

University of Connecticut

Farmington · Connecticut · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
298

Children's National Medical Center

Washington D.C. · District of Columbia · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3CompletedNCT06609226 ↗
299

Foundation for Sickle Cell Disease Research

Hollywood · Florida · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
300

Univ of Miami/SCCC

Miami · Florida · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3CompletedNCT06609226 ↗
301

Emory University School of Medicine

Atlanta · Georgia · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
302

Center for Blood Disorders Augusta University

Augusta · Georgia · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
303

Columbia University Medical Center_New York_0

New York · New York · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
304

Weill Cornell Med Coll-NYPH

New York · New York · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
305

Montefiore Medical Center

The Bronx · New York · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
306

Atrium Levine Children's/Atrium Health

Charlotte · North Carolina · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
307

Duke University_Durham

Durham · North Carolina · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
308

East Carolina University_Greenville

Greenville · North Carolina · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3CompletedNCT06609226 ↗
309

Cincinnati Child's Hsp Med Ctr

Cincinnati · Ohio · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
310

Neuro-Behavioral Clinical Research

North Canton · Ohio · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
311

Medical University Of South Carolina_Charleston

Charleston · South Carolina · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
312

Methodist University Hospital

Memphis · Tennessee · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
313

Texas Children's Hospital_Houston

Houston · Texas · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
314

Versiti, CCBD_Milwaukee

Milwaukee · Wisconsin · United States

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
315

The Hospital for Sick Children

Toronto · Ontario · Canada

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
316

University Health Network - Toronto General Hospital

Toronto · Ontario · Canada

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
317

CHU Ste-Justine

Montreal · Quebec · Canada

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
318

Alexandria University Hospital

Alexandria, Egypt · Egypt

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
319

Zagazig University Hospital

Alsharkia, Egypt · Egypt

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
320

Faculty of Medicine Ain Shams Medical Research Institute (MASRI)

Cairo · Egypt

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
321

Cairo University

Cairo, Egypt · Egypt

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
322

Abu El-Reesh El-Mounira Children University Hospital

Cairo, Egypt · Egypt

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
323

Charité - Campus Virchow-Klinikum - Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

Berlin · Germany

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
324

Universitätsklinikum Freiburg - Kinder- und Jugendklinik

Freiburg im Breisgau · Germany

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
325

Ghana Institute of Clinical Genetics, Korle Bu Teaching Hospital (KBTH)

Accra · Ghana

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
326

General Hospital Of Larissa Koutlibaneio And Triantafylleio - Thalassemia and SCD Unit

Larissa · Thessaly · Greece

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
327

General University Hospital of Patras

Pátrai · Greece

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
328

'Ippokrateio' General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
329

K.J Somaiya Hospital and Research Centre

Mumbai · Maharashtra · India

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
330

Victoria Hospital, Bangalore

Bangalore · India

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
331

Nirmal Hospital Pvt. Ltd.

Gujarat · India

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
332

Suretech Hospital and Research Centre Ltd.

Maharashtra · India

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
333

All India Institute of Medical Sciences_Delhi

New Delhi · India

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
334

Fondazione IRCCS Policlinico San Matteo

Pavia · Italy

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
335

KEMRI-Walter-Reed Kericho

Kericho · Kenya

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
336

Kombewa Clinical Research Centre

Kisumu · Kenya

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
337

KEMRI Kondele Children Hospital, Kisumu

Kisumu · Kenya

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
338

Chronic Care Center

Hazmiyeh · Lebanon

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
339

University of Abuja Teaching Hospital, Gwagwalada, Abuja

Abuja · Nigeria

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
340

Barau Dikko Teaching Hospital, Kaduna

Kaduna · Nigeria

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
341

Aminu Kano Teaching Hospital (AKTH)

Kano · Nigeria

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
342

Prince Mohammad Bin Naser Hospital

Jizan · Saudi Arabia

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
343

Hospital Universitario de Cruces

Barakaldo · Spain

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3ActiveNCT06609226 ↗
344

Baskent Universitesi Adana

Adana · Turkey (Türkiye)

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
345

Evelina London Children's Hospital - Haemophilia

London · United Kingdom

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
346

Guy's Hospital

London · United Kingdom

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3Opening soonNCT06609226 ↗
347

Manchester Royal Infirmary

Manchester · United Kingdom

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
348

Royal Hallamshire Hospital

Sheffield · United Kingdom

1 trial
Long-term safety and effectiveness of etavopivat drug tested in sickle cell disease and thalassaemia patients.
Novo Nordisk A/SPh 3RecruitingNCT06609226 ↗
349

Childrens National Health Center

Washington D.C. · District of Columbia · United States

1 trial
Long-term observational study following sickle cell disease patients to understand disease progression and outcomes.
National Heart, Lung, and Blood Institute (NHLBI)RecruitingNCT00081523 ↗
350

Suburban Hospital

Bethesda · Maryland · United States

1 trial
Long-term observational study following sickle cell disease patients to understand disease progression and outcomes.
National Heart, Lung, and Blood Institute (NHLBI)CompletedNCT00081523 ↗
351

Childrens Healthcare of Atlanta

Atlanta · Georgia · United States

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
352

Levine Cancer Insitute Carolinas Healthcare System

Charlotte · North Carolina · United States

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
353

Univ of Tenn Health Sciences Ctr

Memphis · Tennessee · United States

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
354

U of TX Health Science Ct

Houston · Texas · United States

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
355

Novartis Investigative Site

Edegem · Belgium

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
356

Novartis Investigative Site

Belém · Pará · Brazil

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
357

Novartis Investigative Site

Recife · Pernambuco · Brazil

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
358

Novartis Investigative Site

Rio de Janeiro · Rio de Janeiro · Brazil

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
359

Novartis Investigative Site

Porto Alegre · Rio Grande do Sul · Brazil

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
360

Novartis Investigative Site

Toronto · Ontario · Canada

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
361

Novartis Investigative Site

Montreal · Quebec · Canada

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
362

Novartis Investigative Site

Helsinki · Finland

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
363

Novartis Investigative Site

Marseille · France

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
364

Novartis Investigative Site

Stuttgart · Baden-Wurttemberg · Germany

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
365

Novartis Investigative Site

Cologne · North Rhine-Westphalia · Germany

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
366

Novartis Investigative Site

Berlin · Germany

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
367

Novartis Investigative Site

Essen · Germany

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
368

Novartis Investigative Site

Accra · Ghana

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
369

Novartis Investigative Site

Athens · Greece

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
370

Novartis Investigative Site

Pátrai · Greece

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
371

Novartis Investigative Site

Thessaloniki · Greece

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
372

Novartis Investigative Site

Bhubaneswar · Odisha · India

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
373

Novartis Investigative Site

Hyderabad · Telangana · India

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
374

Novartis Investigative Site

Genova · GE · Italy

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
375

Novartis Investigative Site

Milan · MI · Italy

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
376

Novartis Investigative Site

Verona · VR · Italy

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
377

Novartis Investigative Site

Naples · Italy

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
378

Novartis Investigative Site

Irbid · Jordan

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
379

Novartis Investigative Site

Amsterdam · North Holland · Netherlands

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
380

Novartis Investigative Site

Rotterdam · South Holland · Netherlands

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
381

Novartis Investigative Site

The Hague · South Holland · Netherlands

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
382

Novartis Investigative Site

Panama City · Panama

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
383

Novartis Investigative Site

Soweto · Gauteng · South Africa

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
384

Novartis Investigative Site

Sheffield · United Kingdom

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
385

Novartis Investigative Site

Cambridge · United Kingdom

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
386

Novartis Investigative Site

London · United Kingdom

1 trial
Trial tests two doses of crizanlizumab drug versus placebo in adolescents and adults with sickle cell disease experiencing pain crises.
Novartis PharmaceuticalsPh 3NCT03814746 ↗
387

University Of Alabama

Birmingham · Alabama · United States

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
388

Childrens National Hospital

Washington D.C. · District of Columbia · United States

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
389

Augusta University Georgia

Augusta · Georgia · United States

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4RecruitingNCT04657822 ↗
390

Childrens Hospital of Philadelphia

Philadelphia · Pennsylvania · United States

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
391

Cook Childrens Medical Center

Fort Worth · Texas · United States

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
392

Novartis Investigative Site

Laken · Belgium

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
393

Novartis Investigative Site

Liège · Belgium

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
394

Novartis Investigative Site

Cali · Valle del Cauca Department · Colombia

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
395

Novartis Investigative Site

Heidelberg · Germany

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
396

Novartis Investigative Site

Padova · PD · Italy

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4ActiveNCT04657822 ↗
397

Novartis Investigative Site

Orbassano · TO · Italy

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4CompletedNCT04657822 ↗
398

Novartis Investigative Site

Hatay · Antakya · Turkey (Türkiye)

1 trial
Study provides continued access to crizanlizumab for sickle cell disease patients benefiting from the drug in previous trials.
Novartis PharmaceuticalsPh 4WITHDRAWNNCT04657822 ↗
399

Washington University School of Medicine

St Louis · Missouri · United States

1 trial
Pilot tests a family communication tool to increase youth involvement in stem cell transplant and cellular therapy decisions.
Washington University School of MedicineRecruitingNCT06689800 ↗
400

Children's of Alabama (MRD-HCT)

Birmingham · Alabama · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
401

Children's of Alabama (NT-DMT)

Birmingham · Alabama · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
402

Nemours Children's Hospital, Delaware (MRD-HCT)

Wilmington · Delaware · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
403

Children's National Hospital (MRD-HCT)

Washington D.C. · District of Columbia · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
404

Children's Healthcare of Atlanta (MRD-HCT)

Atlanta · Georgia · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
405

Comer Children's Hospital (MRD-HCT)

Chicago · Illinois · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
406

Riley Children's Hospital (MRD-HCT)

Indianapolis · Indiana · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
407

Riley's Children Hospital (NT-DMT)

Indianapolis · Indiana · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
408

Boston Children's Hospital (MRD-HCT)

Boston · Massachusetts · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
409

Boston Children's Hospital (NT-DMT)

Boston · Massachusetts · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
410

Wahington Univ in St Louis (NT-DMT)

St Louis · Missouri · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
411

Washington University in St Louis (MRD-HCT)

St Louis · Missouri · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
412

Hackensack University Hospital (MRD-HCT)

Hackensack · New Jersey · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
413

Roswell Park (MRD-HCT)

Buffalo · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
414

Columbia Presbytarian (NT-DMT)

New York · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
415

Cohen's Children Hospital (NT-DMT)

Queens · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
416

University of Rochester (MRD-HCT)

Rochester · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
417

University of Rochester (NT-DMT)

Rochester · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
418

Children's Hospital at Montefiore (MRD HCT)

The Bronx · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
419

Children's Hospital at Montefiore (NT-DMT)

The Bronx · New York · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
420

UNC Children's Hospital (MRD HCT)

Chapel Hill · North Carolina · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
421

UNC Children's Hospital (NT-DMT)

Chapel Hill · North Carolina · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
422

Atrium Health (MRD-HCT)

Charlotte · North Carolina · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
423

Nationwide Children's Hospital (NT-DMT)

Columbus · Ohio · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
424

Oklahoma Children's Hospital (MRD-HCT)

Oklahoma City · Oklahoma · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
425

Children's Hospital of Philadelphia (MRD-HCT)

Philadelphia · Pennsylvania · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
426

St Jude Children Hospital (NT-DMT)

Memphis · Tennessee · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
427

St. Jude Children's Research Hospital (MRD-HCT)

Memphis · Tennessee · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
428

Texas Children's Hopsital (NT-DMT)

Houston · Texas · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
429

Texas Children's Hospital (MRD-HCT)

Houston · Texas · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
430

UT San Antonio (NT-DMT)

San Antonio · Texas · United States

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
431

Alberta Children's Hospital (NT-DMT)

Calgary · Alberta · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
432

Alberta Children's Hospital (MRD-HCT)

Calgary · Alberta · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
433

British Columbia Children's Hosptial (MRD HCT)

Vancouver · British Columbia · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
434

HSC Winnipeg Children's Hospital/University of Manitoba (MRD-HCT)

Winnipeg · Manitoba · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterRecruitingNCT06941389 ↗
435

The Hospital for Sick Children (MRD-HCT)

Toronto · Ontario · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
436

Universite de Montreal / Ste Justine (MRD HCT)

Montreal · Quebec · Canada

1 trial
Study compares long-term outcomes of stem cell transplant versus non-transplant therapies in children with sickle cell disease.
University of RochesterOpening soonNCT06941389 ↗
437

Children's Hospital of Colorado

Aurora · Colorado · United States

1 trial
Trial adds ruxolitinib drug to transplant conditioning to reduce graft failure in children with sickle cell disease.
Arkansas Children's Hospital Research InstitutePh 1 / Ph 2Opening soonNCT07252050 ↗
438

Children's Healthcare of Atlanta

Atlanta · Georgia · United States

1 trial
Trial adds ruxolitinib drug to transplant conditioning to reduce graft failure in children with sickle cell disease.
Arkansas Children's Hospital Research InstitutePh 1 / Ph 2RecruitingNCT07252050 ↗
439

Manning Family Children's

New Orleans · Louisiana · United States

1 trial
Trial adds ruxolitinib drug to transplant conditioning to reduce graft failure in children with sickle cell disease.
Arkansas Children's Hospital Research InstitutePh 1 / Ph 2Opening soonNCT07252050 ↗
440

Children's Hospital of Philadelphia

Philadelphia · Pennsylvania · United States

1 trial
Trial adds ruxolitinib drug to transplant conditioning to reduce graft failure in children with sickle cell disease.
Arkansas Children's Hospital Research InstitutePh 1 / Ph 2Opening soonNCT07252050 ↗
441

Masonic Cancer Center

Minneapolis · Minnesota · United States

1 trial
Phase II trial tests allogeneic stem cell transplantation for high-risk blood disorders including sickle cell disease.
Masonic Cancer Center, University of MinnesotaPh 2RecruitingNCT06872333 ↗
442

Children's Hospital of Illinois at OSF-Saint Francis Medical Center

Peoria · Illinois · United States

1 trial
Research program studies long-term organ damage and health outcomes in adults with sickle cell disease.
St. Jude Children's Research HospitalRecruitingNCT02098863 ↗
443

Our Lady of the Lake Regional Medical Center

Baton Rouge · Louisiana · United States

1 trial
Research program studies long-term organ damage and health outcomes in adults with sickle cell disease.
St. Jude Children's Research HospitalCompletedNCT02098863 ↗
444

Novant Health Hemby Children's Hospital

Charlotte · North Carolina · United States

1 trial
Research program studies long-term organ damage and health outcomes in adults with sickle cell disease.
St. Jude Children's Research HospitalRecruitingNCT02098863 ↗
445

Regional One Health, Diggs-Kraus Sickle Cell Center

Memphis · Tennessee · United States

1 trial
Research program studies long-term organ damage and health outcomes in adults with sickle cell disease.
St. Jude Children's Research HospitalRecruitingNCT02098863 ↗
446

Methodist Adult Comprehensive Sickle Cell Center

Memphis · Tennessee · United States

1 trial
Research program studies long-term organ damage and health outcomes in adults with sickle cell disease.
St. Jude Children's Research HospitalRecruitingNCT02098863 ↗
447

Augusta University

Augusta · Georgia · United States

1 trial
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
448

Innovative Hematology - Indiana Hemophilia & Thrombosis Center

Indianapolis · Indiana · United States

1 trial
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗
449

Mount Sinai Hospital

New York · New York · United States

1 trial
DISC-3405 drug safety and dosing study in adults and children with sickle cell disease.
Disc Medicine, IncPh 1RecruitingNCT07187973 ↗